DoD Kidney Cancer Research Program
Clinical Trial Award
Amount of funding: Direct costs budgeted will not exceed $2,000,000
Purpose: The KCRP Clinical Trial Award supports the rapid implementation of early-phase clinical trials (phase 0, phase 1, phase 1/2) with the potential to have a significant impact on the treatment or management of kidney cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, surgical procedures, behavior DoD FY21 Kidney Cancer Clinical Trial Award 5 modifications, clinical guidance, and/or emerging approaches and technologies. Therapeutic approaches testing existing interventions for new indications in kidney cancer are also encouraged. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform kidney cancer patient care.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be the Initiating PI or Partnering PI.
Not eligible: Stanford Instructors, Clinical Instructors, Academic Staff-research, and Postdocs are not eligible because Stanford does not consider them to be independent or faculty level positions.
Pre-application/Letter of intent (required) deadline: September 14, 2021, 5pm ET via eBrap
Please include your RPM’s name as business official in the pre-application
Institutional representative (RPM/RMG or CGO/OSR) deadline: September 28, 2021
Full proposal deadline: October 5, 2021, 11:59 pm ET via grants.gov